Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
K - The guy on that broadcast is universally regarded as a sensationalist, conspiracy kook and nutball.
While Im broken hearted about what's going on in your area I'm not convinced this guy has spewed anything but another fantastic yarn to get attention again. Radio talk shows love his kind of schtick cuz it "sells" almost as good as sex does for tv. It's what he does for a living.
Ahhh, most wisely said Master Po
"Caine: Is it good to seek the past, Master Po? Does it not rob the present?
Master Po: If a man dwells on the past, then he robs the present. But if a man ignores the past, he may rob the future. The seeds of our destiny are nurtured by the roots of our past. "
lol
s
Added too, RTN
Avgin down is a no no in my rule book but this will be worth the exemption.
ONTY announces Merck Serono resuming Stimuvax clinical program in lung cancer
8:00 am ET 06/17/2010 - PR Newswire
SEATTLE, WA, June 17 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., are resuming the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine) in non-small cell lung cancer (NSCLC), including the Phase 3 START and INSPIRE trials. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees. The announcement follows a decision by the U.S. Food and Drug Administration (FDA) to partially lift the clinical hold it placed on the Investigational New Drug (IND) application for BLP25 liposome vaccine in March 2010 and allow the START trial to be resumed.
ONTY announces Merck Serono resuming Stimuvax clinical program in lung cancer
8:00 am ET 06/17/2010 - PR Newswire
SEATTLE, WA, June 17 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., are resuming the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine) in non-small cell lung cancer (NSCLC), including the Phase 3 START and INSPIRE trials. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees. The announcement follows a decision by the U.S. Food and Drug Administration (FDA) to partially lift the clinical hold it placed on the Investigational New Drug (IND) application for BLP25 liposome vaccine in March 2010 and allow the START trial to be resumed.
ECTY- The EV Project Expands to LA, Washington, D.C.
I've been adding to clean energy plays since April, very thin - only 9M sharesOS, runs when the wind blows
8:00 am ET 06/17/2010- Business Wire
Adds $30 Million to The EV Project, Adds 2600 Chevrolet Volt and 1,000 Nissan LEAF Vehicles
TEMPE, Ariz.--(BUSINESS WIRE)-- Ecotality, Inc. (NASDAQ:ECTY), a leader in clean electric transportation and storage technologies, announced today that the U.S. Department of Energy has expanded The EV Project to include two new cities ?ldquo; Los Angeles, California and Washington, D.C. ?ldquo; and has broadened the offer of free home chargers to include qualified new owners of the Chevrolet Volt electric vehicle with extended-range capability. The expansion also adds an additional 1,000 Nissan LEAF zero-emission cars to the Project.
This expansion will be funded by a $30 millionU.S. Department of Energy grant extension to ECOtality's EV Project, which was created through the American Recovery and Reinvestment Act (ARRA). This new Federal grant extension includes $15 million of ARRA funding, which will be matched with $15 million in private funds, to reach the total of $30 million. ECOtality is the project manager for The EV Project, which began in October 2009 with an original grant amount of $99.8 million and the objective of creating new jobs, jump-starting the economy, reducing greenhouse gas emissions and lessening the country's dependence on fossil fuel. With the assistance of more than forty partners, The EV Project will deliver nearly 15,000 residential and commercial chargers to 13 cities in five states and the District of Columbia. The mission of the Project is to evaluate the use of electric vehicles and charging systems in diverse geographies and climates, then to use that information to build a foundation that will optimize adoption of electric vehicles nationwide.
With this expansion, ECOtality's EV Project, already the largest electric vehicle infrastructure project ever undertaken, will provide an additional 2,600 home chargers for owners of the Chevrolet Volt, as well as another 1,000 chargers for the zero-emission Nissan LEAF electric vehicles.
“Americans are ready to think differently about how they drive, and are ready to embrace electric vehicle technology,” said ECOtality CEO & President Jonathan Read. “Through The EV Project, ECOtality is meeting the demand for new fuel sources by making EV charging simple, smart and available to everyone.”
"Nissan is looking forward to bringing the Nissan LEAF and sustainable mobility to Los Angeles," said Eric Noziere, vice president, Corporate Planning, Nissan North America. "We have seen tremendous interest through early reservations from LA consumers. These 1,000 Nissan LEAF 100% electric cars and supporting charging infrastructure will help create a successful environment for electric vehicles as we approach the December launch of the Nissan LEAF. In total, Nissan is supporting The EV Project through 5,700 vehicles, nationwide."
The mission of The EV Project is to collect and study data that will ultimately characterize how consumers actually use EVs in a wide range of climate conditions and geographies, as well as to create a model that will allow charging infrastructure to grow throughout the United States as a sustainable, stand-alone business that does not require long-term government support. Inclusion of the Volt now allows for the study of performance and use patterns for electric vehicles with extended-range capability.
“Many Volt owners will plug their Volt into a normal 120-volt electrical outlet, charge overnight and drive to work in the morning using only battery power,” said Tony DiSalle, Product and Marketing Director for the Chevrolet Volt. “For Volt owners who want to install a faster 240-volt charge station, we expect The EV Project to save them a significant amount of money. In addition, The EV Project enables Volt owners to play a role in developing our collective understanding of electric vehicles in the market.”
ECOtality North America President and CEO Don Karner said, “We are very excited to expand our studies to include additional Nissan LEAF vehicles, to add the Chevrolet Volt, and to add the dynamic transportation environments of Los Angeles and Washington, D.C. Since The EV Project began last October, we have been busy working with regional stakeholders to plan an effective charge infrastructure deployment. We will soon be entering a new phase of The EV Project to deploy chargers in accordance with these plans.”
ECOtality will present EV Project charge hardware in San Jose at Plug-In 2010, July 26 - 29th. For more information about The EV Project, please visit www.theevproject.com.
ECTY- The EV Project Expands to LA, Washington, D.C.
I've been adding to clean energy plays since April, very thin - only 9M sharesOS, runs when the wind blows
8:00 am ET 06/17/2010- Business Wire
Adds $30 Million to The EV Project, Adds 2600 Chevrolet Volt and 1,000 Nissan LEAF Vehicles
TEMPE, Ariz.--(BUSINESS WIRE)-- Ecotality, Inc. (NASDAQ:ECTY), a leader in clean electric transportation and storage technologies, announced today that the U.S. Department of Energy has expanded The EV Project to include two new cities ?ldquo; Los Angeles, California and Washington, D.C. ?ldquo; and has broadened the offer of free home chargers to include qualified new owners of the Chevrolet Volt electric vehicle with extended-range capability. The expansion also adds an additional 1,000 Nissan LEAF zero-emission cars to the Project.
This expansion will be funded by a $30 millionU.S. Department of Energy grant extension to ECOtality's EV Project, which was created through the American Recovery and Reinvestment Act (ARRA). This new Federal grant extension includes $15 million of ARRA funding, which will be matched with $15 million in private funds, to reach the total of $30 million. ECOtality is the project manager for The EV Project, which began in October 2009 with an original grant amount of $99.8 million and the objective of creating new jobs, jump-starting the economy, reducing greenhouse gas emissions and lessening the country's dependence on fossil fuel. With the assistance of more than forty partners, The EV Project will deliver nearly 15,000 residential and commercial chargers to 13 cities in five states and the District of Columbia. The mission of the Project is to evaluate the use of electric vehicles and charging systems in diverse geographies and climates, then to use that information to build a foundation that will optimize adoption of electric vehicles nationwide.
With this expansion, ECOtality's EV Project, already the largest electric vehicle infrastructure project ever undertaken, will provide an additional 2,600 home chargers for owners of the Chevrolet Volt, as well as another 1,000 chargers for the zero-emission Nissan LEAF electric vehicles.
“Americans are ready to think differently about how they drive, and are ready to embrace electric vehicle technology,” said ECOtality CEO & President Jonathan Read. “Through The EV Project, ECOtality is meeting the demand for new fuel sources by making EV charging simple, smart and available to everyone.”
"Nissan is looking forward to bringing the Nissan LEAF and sustainable mobility to Los Angeles," said Eric Noziere, vice president, Corporate Planning, Nissan North America. "We have seen tremendous interest through early reservations from LA consumers. These 1,000 Nissan LEAF 100% electric cars and supporting charging infrastructure will help create a successful environment for electric vehicles as we approach the December launch of the Nissan LEAF. In total, Nissan is supporting The EV Project through 5,700 vehicles, nationwide."
The mission of The EV Project is to collect and study data that will ultimately characterize how consumers actually use EVs in a wide range of climate conditions and geographies, as well as to create a model that will allow charging infrastructure to grow throughout the United States as a sustainable, stand-alone business that does not require long-term government support. Inclusion of the Volt now allows for the study of performance and use patterns for electric vehicles with extended-range capability.
“Many Volt owners will plug their Volt into a normal 120-volt electrical outlet, charge overnight and drive to work in the morning using only battery power,” said Tony DiSalle, Product and Marketing Director for the Chevrolet Volt. “For Volt owners who want to install a faster 240-volt charge station, we expect The EV Project to save them a significant amount of money. In addition, The EV Project enables Volt owners to play a role in developing our collective understanding of electric vehicles in the market.”
ECOtality North America President and CEO Don Karner said, “We are very excited to expand our studies to include additional Nissan LEAF vehicles, to add the Chevrolet Volt, and to add the dynamic transportation environments of Los Angeles and Washington, D.C. Since The EV Project began last October, we have been busy working with regional stakeholders to plan an effective charge infrastructure deployment. We will soon be entering a new phase of The EV Project to deploy chargers in accordance with these plans.”
ECOtality will present EV Project charge hardware in San Jose at Plug-In 2010, July 26 - 29th. For more information about The EV Project, please visit www.theevproject.com.
About ECOtality, Inc.
ECOtality, Inc. (NASDAQ:ECTY), headquartered in Tempe, Arizona, is a leader in clean electric transportation and storage technologies. Through innovation, acquisitions, and strategic partnerships, ECOtality accelerates the market applicability of advanced electric technologies to replace carbon-based fuels. For more information about ECOtality, Inc., please visit www.ecotality.com.
Kgoodrich...
Ken, I'm lousy at trying to find the right words that would aid or comfort in this sad time but to know he was surrounded by family is a powerful statement of the bonds you all felt and I'm sure he felt those above all else.
Steve
IMUC- ImmunoCellular Therapeutics Granted Orphan Drug Status for ICT-107
9:43 am ET 06/11/2010- Business Wire
LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme (GBM). As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years. US orphan drug designation is granted to companies with products aimed at treatment of a rare disease or condition that affects fewer than 200,000 Americans.
A recent Phase I clinical study of ICT-107 in GBM revealed that newly diagnosed patients who received the vaccine demonstrated a median progression-free survival (PFS) of 17.7 months after surgery, compared with the historical median PFS of 6.9 months observed with standard treatment with surgery, radiation and chemotherapy. Seven of the 16 patients (44%) who participated in the study went on to live with no disease progression with an average time over 2 years, significantly better than historical data of less than 15% disease free survival. The drug has exceeded its competitors in the overall survival rate in newly diagnosed GBM patients by demonstrating an 80% survival, which is about three times larges than the historical control.
"We are pleased that FDA has recognized the potential that ICT-107 has to treat GBM and has granted us orphan drug status”, said ImmunoCellular Therapeutics' president and CEO said Manish Singh, Ph.D. "The designation should facilitate a shorter time period to approval and reflects the FDA's views on the importance of developing a treatment which will improve survival outcomes for those afflicted with this terrible disease."
The 12-month disease-free survival from the time of surgery was 75% with ICT-107, compared with a historical control survival rate of 26.9%, and the 18-month disease-free survival with ICT-107 was 49.2%, compared with 18.4% historically. Safety data for ICT-107 also compared favorably to current treatments: no serious adverse events were reported and minor side effects were limited to fatigue, skin rash and pruritis.
About ImmunoCellular Therapeutics, Ltd.
xela's CBAK news, announces preferred vendor agreemnent w/ Micro Power Electonics
A.F. is a paid mouthpiece!
Everyone's differing opinions regarding his work, credentials, influence, etc. have merit. Bottom line is he doesn't have an original thought and is pushing the adgenda of those who pay him. It does pay to play those issues he riding and whether his writings are right or wrong don't matter to the emotionally detached traders who play his work.
glta
s
GETA volume appears avg @ 32M/day over the last 60 days...especially using those #'s kei provided
Perrigo Co. (PRGO) Announces U.S. FDA Approval of Generic Monistat -1 Combo Pack
8:41 AM ET - StreetInsider
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter Miconazole Nitrate Vaginal Cream and Suppository, a generic to Monistat -1 Combination Pack. Monistat-1 has annual retail sales of approximately $90 million dollars
CEPH announced the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal. The analysis of the data showed that treatment with armodafinil did not lessen the severity of the negative symptoms of schizophrenia compared to placebo in the 24-week study. As a result of the outcome of this trial, Cephalon has decided not to move forward with this clinical program.
Figures that p.o.s. FCEL gets it on before I revive some DD on it.
FuelCell Energy to Supply Direct FuelCell Power Plants to California Utility
8:30 am ET 06/03/2010- GlobeNewswire
DANBURY, Conn., June 3, 2010 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq:FCEL) a leading manufacturer of high efficiency ultra-clean power plants using renewable and other fuels for commercial, industrial, government, and utility customers today announced that Pacific Gas and Electric Company (PG&E) has ordered two 1.4 Megawatt DFC1500 fuel cell power plants to install as utility-owned fuel cells on the campuses of California State University East Bay -- Hayward Hills (CSU -- East Bay) and San Francisco State University (SFSU). The total value of these contracts is approximately $12.6 million, which will include engineering, procurement and construction services for the installation of the power plants.
This order follows the recent approval by the California Public Utilities Commission (CPUC) for PG&E to pursue utility owned fuel cell installations at two California universities. The CPUC approval acknowledged that the installation of fuel cells on university campuses will help to advance the development and understanding of fuel cell technology. Further, the CPUC noted the important role of fuel cells in the State's future energy mix, as illustrated by the support of Governor Schwarzenegger for fuel cell projects.
"Just as California is serving as a model for the rest of the nation in enacting ambitious policies to reduce climate change and our dependency on oil, these partnerships are also leading the way in moving us toward a cleaner, more sustainable future," said Governor Schwarzenegger. "Fuel cells are another great resource to provide clean and efficient energy while reducing emissions. I applaud all of these groups for coming together and working towards a shared solution of helping to power these campuses with clean energy."
The fuel cell power plants will be configured to utilize the by-products of the fuel cell energy conversion process, including waste heat and waste water to meet campus needs. CSU East Bay plans to utilize the waste heat for heating a swimming pool and utilize the waste water for landscape irrigation. SFSU plans to utilize the waste heat for facility management. The fuel cell plants are expected to be operational in 2011. In conjunction with the installation of the fuel cell power plants, the state universities are expected to incorporate fuel cell technology into their respective curriculums to teach students and the public about the benefits of fuel cell systems.
"We are excited to be working with PG&E to be providing a utility owned power generation solution that is highly efficient and ultra-clean," commented R. Daniel Brdar, Chairman and CEO of FuelCell Energy, Inc. "Universities are an ideal location for our fuel cell power plants, particularly with the Combined Heat & Power (CHP) application that captures the heat byproduct for use by the university. This type of CHP application has attained efficiency levels approaching 80%, well above alternate methods for generating electricity."
FCEL busy premkt - FuelCell Energy to Supply Direct FuelCell Power Plants to California Utility
8:30 am ET 06/03/2010- GlobeNewswire
DANBURY, Conn., June 3, 2010 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq:FCEL) a leading manufacturer of high efficiency ultra-clean power plants using renewable and other fuels for commercial, industrial, government, and utility customers today announced that Pacific Gas and Electric Company (PG&E) has ordered two 1.4 Megawatt DFC1500 fuel cell power plants to install as utility-owned fuel cells on the campuses of California State University East Bay -- Hayward Hills (CSU -- East Bay) and San Francisco State University (SFSU). The total value of these contracts is approximately $12.6 million, which will include engineering, procurement and construction services for the installation of the power plants.
This order follows the recent approval by the California Public Utilities Commission (CPUC) for PG&E to pursue utility owned fuel cell installations at two California universities. The CPUC approval acknowledged that the installation of fuel cells on university campuses will help to advance the development and understanding of fuel cell technology. Further, the CPUC noted the important role of fuel cells in the State's future energy mix, as illustrated by the support of Governor Schwarzenegger for fuel cell projects.
"Just as California is serving as a model for the rest of the nation in enacting ambitious policies to reduce climate change and our dependency on oil, these partnerships are also leading the way in moving us toward a cleaner, more sustainable future," said Governor Schwarzenegger. "Fuel cells are another great resource to provide clean and efficient energy while reducing emissions. I applaud all of these groups for coming together and working towards a shared solution of helping to power these campuses with clean energy."
The fuel cell power plants will be configured to utilize the by-products of the fuel cell energy conversion process, including waste heat and waste water to meet campus needs. CSU East Bay plans to utilize the waste heat for heating a swimming pool and utilize the waste water for landscape irrigation. SFSU plans to utilize the waste heat for facility management. The fuel cell plants are expected to be operational in 2011. In conjunction with the installation of the fuel cell power plants, the state universities are expected to incorporate fuel cell technology into their respective curriculums to teach students and the public about the benefits of fuel cell systems.
"We are excited to be working with PG&E to be providing a utility owned power generation solution that is highly efficient and ultra-clean," commented R. Daniel Brdar, Chairman and CEO of FuelCell Energy, Inc. "Universities are an ideal location for our fuel cell power plants, particularly with the Combined Heat & Power (CHP) application that captures the heat byproduct for use by the university. This type of CHP application has attained efficiency levels approaching 80%, well above alternate methods for generating electricity."
CBAK - China BAK CFO Interviewed by Dow Jones Investment Banker
8:00 am ET 06/03/2010- PR Newswire
SHENZHEN, China, June 3 /PRNewswire-Asia-FirstCall/ -- China BAK Battery,Inc. ("China BAK" or the "Company") (Nasdaq: CBAK), a leading globalmanufacturer of lithium-based battery cells, today announced that theCompany's Chief Financial Officer, Mr. Jun Zou, was featured in a live videointerview with Greg Millman of Dow Jones Investment Banker.
The interview covered the Company's success as the first Chinese companyto go public via an alternative public offering and reverse merger in 2005 andits subsequent listing on the NASDAQ. During the interview, Mr. Zou explainedthat China BAK enjoys a strong support from local banks due to its standing asa leading manufacturer in Shenzhen and established credit history. He alsoaddressed concerns regarding the Company's capital structure and discussed hisstrategy to turn around the Company by improving working capital, operatingcash flow, and manufacturing cost.
The interview has been published by Dow Jones Investment Banker and isavailable online on the Company's website athttp://www.bak.com.cn/xinxi-xiangxi.asp?id=544
ARQL - PREVIEW-Investors seek clarity on ArQule trial plan
8:00 am ET 06/03/2010- Reuters
* What: ArQule to present detailed mid-stage data at ASCO
* When: June 5
* Shares more than doubled with Phase II results in March
* Investors look for parameters on Phase III trial
By Deena Beasley
LOS ANGELES, June 3 (Reuters) - ArQule Inc <ARQL.O> on Saturday will present detailed trial results for its experimental lung cancer drug, which investors hope will help define the next step for a pivotal trial program.
The details could spell the difference between a potential biotech success story and a return to the trenches of early-stage drug discovery.
Shares of the company, based in Woburn, Massachusetts, have risen about 56 percent so far this year, but still trade at less than half their 1996 initial public offering price of $12.25. In March, the shares doubled in value to a year high of $7.49 in one day when the company posted the Phase II trial summary for the drug, known as ARQ197.
"What I would like to see at ASCO (American Society of Clinical Oncology) is good identification of a population of patients that they will then go into the Phase III trial with," said George Zavoico, an analyst at McNicoll, Lewis and Vlak.
ArQule's data will be presented at the ASCO annual meeting in Chicago.
The company said in March that the Phase II trial of the drug, used in combination with Tarceva, showed a 66 percent improvement in the amount of time patients lived without their cancer worsening, compared with use of Tarceva alone.
ARQ197 is part of a potential new class of cancer drugs designed to block a protein, called C-met, involved in cancer cell growth and survival.
But the trial of 167 patients with advanced non-small cell lung cancer achieved statistical significance only after adjusting for "molecular factors," such as whether a patient's tumor had a genetic mutation in the epidermal growth factor receptor (EGFR) or KRAS gene, said ArQule spokesman William Boni.
Tarceva, which is designed to target EGFR, is sold by Roche AG <ROG.VX> and OSI Pharmaceuticals Inc <OSIP.O>.
In the sub-group of patients with non-squamous lung cancer, ArQule said the drug combination improved survival with no cancer growth by 94 percent. Non-squamous is the most common type of non-small cell lung cancer.
"We expect ArQule to begin a Phase III program for ARQ197 plus Tarceva in non-squamous NSCLC in second-half 2010," Oppenheimer analyst Bret Holley said in a research note.
ArQule began life as a provider of contract chemistry services to drugmakers, but that business model fell apart as drugmakers shifted to lower-cost centers in China and elsewhere.
A key step in the transformation from a combinatorial chemistry company to a drug developer was its 2003 acquisition of Cyclis Pharmaceuticals.
In 2008, ArQule hired Paolo Pucci, formerly a senior vice president at Bayer AG <BAYGn.DE>, as its chief executive. Brian Schwartz, also a former executive at Bayer, was brought in as chief medical officer.
The pair had helped to develop targeted cancer drug Nexavar, which is sold by Bayer and Onyx Pharmaceuticals Inc <ONXX.O>.
ArQule, in partnership with with Japan's Daiichi Sankyo <4568.T>, is testing ARQ 197 in several different types of cancer. (Reporting by Deena Beasley; Editing by Steve Orlofsky)
In light of administrations "Think green/clean energy or else" speech today and on the heals of the gulf spill and Oblame-ah's strongest props yet regarding clean energys, I'm going to realocate ASCO plays and continue taking positions in elec. cars/rechargable batt grid/natgas issues.
Some to consider: ECTY, CLNE, AONE, ARTX, AZDDF, NGAS, FSYS, and HEV. Maybe the p.o.s. FCEL and PLUG but need to look into those again, been awhile.
Input, comments greatly appreciated.
gla
S
Hey KG - What's the chatter about the use of a nuclear option to shut down the spill?
In light of administrations "Think green/clean energy or else" speech today am going to realocate ASCO plays and continue taking positions in elec. cars/rechargable batt grid/natgas issues.
Some to consider: ECTY, CLNE, AONE, ARTX, AZDDF, NGAS, FSYS, and HEV. Maybe the p.o.s. FCEL and PLUG but need to look into those again, been awhile.
Input, comments appreciated.
gla
S
ALXA nice spike into close
IMUC - 6Xavgvol ahead of ASCO presentation, news, tiny float...
I'll ride it to 2.44 watching how it manages resistance @ 2 and 2.44.
This a momo play, only on phase one of this treatments journey. Has one analyst tgt of $3.25.
btw, BMR late on this one. they didn't get it on their site until after us :^)
IMUC only 19M shares outstanding, 4x avg vol already, could scream.
thnx cccpmd for full article posting
ALIM ittybitty float, popping
IMUC - Nice Letter to Shareholders & itty bitty float could get interesting
ImmunoCellular Therapeutics, Ltd. Issues Letter to Shareholders
8:30 am ET 05/26/2010- Business Wire
LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics. Ltd. or “IMUC” (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, issued the following Letter to Shareholders today:
Dear Shareholder:
I wanted to update you on ImmunoCellular corporate and industry developments over the past six months, since my last letter to you. Today, your company is very different than it was in mid-November. We have announced promising clinical results for ICT-107, our dendritic cell-based cancer vaccine which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors, strengthened our balance sheet to fund a planned Phase II clinical trial of ICT-107 and seen a validation of immunotherapy as a treatment modality through Dendreon's FDA clearance. These developments have positioned IMUC to create significant shareholder value in 2010 and beyond.
Some of the recent highlights include:
Strengthened balance sheet. In the last three months alone, the Company has raised approximately $8.5 million. We will continue to manage our cash conservatively, which historically has resulted in cash consumption of approximately $650,000 per quarter. Of course, our cash expenditures will increase as we accelerate our clinical and other research and development activities, but we should now have sufficient working capital to initiate and complete patient enrollment forour Phase II trial for ICT-107 and to pursue other clinical programs.
Reported impressive Phase I results for ICT-107 in a GBM trial. The Company recently announced top-line results, which demonstrated a median progression free survival for patients who received the vaccine of 17.7 months. We will be presenting new data on 18 and 24-month disease free survival and overall survival, as well as the full results of the trial at the 2010 American Society of Clinical Oncology Annual Meeting in Chicago on June 6th. While this trial involved a limited number of patients, we believe that this data represents the most impressive results reported to date from any trial for a GBM vaccine.
Sought Orphan Drug Status for ICT-107. The Company submitted an application for orphan drug status for ICT-107 in May and anticipates approval within the next 90 days.
The Company recently entered into a sponsored research agreement and an option agreement with The University of Pennsylvania (“UPenn”) to support process development and manufacturing for the upcoming Phase II clinical trial of ICT-107. The UPenn agreement will include process optimization with the goal of increasing yields such that in a single manufacturing run enough doses could be produced for 2-3 years of each patient's vaccination and reduce the cost of manufacturing of each dose significantly. In addition, the optioned dendritic cell production technologies developed at UPenn could result in a higher potency as well as reduced time to manufacture these vaccines.
As part of our efforts to broaden the applications for our cancer vaccine technology platform, we have shown that our dendritic cell-based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in a preclinical animal model of GBM. The rats were either immunized with cancer stem cells (CSCs) from a brain cancer tumor or the daughter cells (the bulk of the tumor), and results showed that those immunized with the CSCs had a median survival of 50 days compared to 29 days for daughter cells. 30% of the animals vaccinated against cancer stem cells demonstrated long term survival as compared to animals vaccinated with the bulk of the tumor, all of which died.
We also continue to develop other cancer vaccine programs. We recently reported that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells (“CSCs”) which makes it promising for immunological targeting. The parties have extended their research agreement to pursue additional studies to support an Investigational New Drug Application (IND) filing for ICT-121, our “off the shelf” cancer vaccine candidate for GBM, and other solid tumor cancers, as well as research on other cancer stem cell targets such as Numb and Notch proteins which are expressed on CSCs. Additional pre-clinical studies are underway to support the IND filing, which we hope to make in late2010.
Our industry also made a significant achievement this year, in the announcement of the approval of Dendreon Corporation's prostate cancer vaccine by the FDA, which will result in the introduction of the first therapy utilizing the body's immune system to destroy tumors. The approval marks the first cancer immunotherapy product approved in the U.S., and we believe that it helps to validate immunotherapy treatments such as ours as a promising way to treat cancer. Our company is developing the next-generation of cancer vaccines by targeting multiple antigens and targeting cancer stem cells, widely held to be the root of most forms of cancer.
We are excited to present data at ASCO and to commence a Phase II trial in GBM this year to validate the promising results to date. We look forward to sharing these, and other corporate developments with our shareholders in the coming months.
Sincerely,Manish Singh, Ph.D.President and CEO
VVUS ramping...news?
bot IMUC - ImmunoCellular Therapeutics’ ICT-107 Demonstrates 80 Percent Survival at 2 Years in Phase I Study of Newly Diagnosed Glioblastoma Patients
8:00 AM ET - Business Wire
Data to Be Presented at Annual Meeting of American Society of Clinical Oncology.
bot IMUC - ImmunoCellular Therapeutics’ ICT-107 Demonstrates 80 Percent Survival at 2 Years in Phase I Study of Newly Diagnosed Glioblastoma Patients
8:00 AM ET - Business Wire
Data to Be Presented at Annual Meeting of American Society of Clinical Oncology.
bot IMUC - ImmunoCellular Therapeutics’ ICT-107 Demonstrates 80 Percent Survival at 2 Years in Phase I Study of Newly Diagnosed Glioblastoma Patients
8:00 AM ET - Business Wire
Data to Be Presented at Annual Meeting of American Society of Clinical Oncology.
ALIM on radar - Three PT's $15-16
CS,Oppenheimer,Citi out w/ pt's $15-16
Business Summary
http://www.alimerasciences.com/
Alimera Sciences, Inc. is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien, which the Company is developing for the treatment of diabetic macular edema (DME). The Company has completed enrollment of 956 patients in two Phase 3 pivotal clinical trials for the use of Iluvien in the treatment of DME across the United States, Canada, Europe and India. Iluvien is an intravitreal insert designed to provide a sustained therapeutic effect for up to 36 months by delivering a low daily dose of fluocinolone acetonide (FA), a corticosteroid with demonstrated efficacy in the treatment of ocular diseases. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound.
BSDM - BSD Medical Reports Impressive Results from Clinical Study on Pancreatic Cancer Presented at ESHO 2010 Meeting
9:00 AM ET - Business Wire
BSD Medical Corporation today reported impressive results from a clinical study on the use of hyperthermia, delivered using the BSD-2000 Hyperthermia System, to treat pancreatic cancer.
added ECTY vol 3x avg...FSYS, HEV, ZAAP on watch (natgas, phev/hev/ev technologies) especially in this think green/"lets kill the oil industry" environment
OT - Nuclear option gaining traction to stop gulf spill
gov't has sent nuclear physicists and scientists to evaluate.
http://www.oil-price.net/en/articles/nukes-to-stop-the-oil-gusher.php
any chatter about that Kg?
ALXA - Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
4:10 pm ET 05/26/2010- PR Newswire
MOUNTAIN VIEW, Calif., May 26 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has obtained a committed equity financing facility under which it may sell up to $25 million of its registered common stock to Azimuth Opportunity, Ltd. over a 24-month period. Alexza is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions. This facility replaces a similar facility that was established in March 2008 and expired after its 24-month term.
"This flexible financing facility is an important component of our portfolio of financing options, giving us the potential ability to raise capital quickly, at a competitive cost, and it may allow us to manage dilution more effectively by issuing shares in multiple tranches at times of our choosing over the next 24 months," said August J. Moretti, Senior Vice President and Chief Financial Officer of Alexza. "We believe these advantages could benefit Alexza and our stockholders as we continue to transition from the development stage to commercialization."
"This is an exciting time for Alexza. As our October 11, 2010 PDUFA goal date approaches, we continue to scale-up our commercial manufacturing, and we are working with Biovail for the expected launch of our lead program AZ-004 (Staccato?reg; loxapine) in Q1 2011," said Thomas B. King, President and CEO of Alexza.
Alexza will determine, at its sole discretion, the timing, the dollar amount and the floor price per share of each draw under this facility, subject to certain conditions. When and if Alexza elects to use the facility, Alexza will issue shares to Azimuth at a small discount to the volume weighted average price of Alexza's common stock over a preceding period of trading days. Reedland Capital Partners, an Institutional Division of Financial West Group, Member FINRA/SIPC, will act as placement agent and receive a fee for its services at the time of any draw under the facility. Any shares sold under this facility will be sold pursuant to a shelf registration statement declared effective by the Securities and Exchange Commission on May 20, 2010.
ALXA - Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
4:10 pm ET 05/26/2010- PR Newswire
MOUNTAIN VIEW, Calif., May 26 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has obtained a committed equity financing facility under which it may sell up to $25 million of its registered common stock to Azimuth Opportunity, Ltd. over a 24-month period. Alexza is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions. This facility replaces a similar facility that was established in March 2008 and expired after its 24-month term.
"This flexible financing facility is an important component of our portfolio of financing options, giving us the potential ability to raise capital quickly, at a competitive cost, and it may allow us to manage dilution more effectively by issuing shares in multiple tranches at times of our choosing over the next 24 months," said August J. Moretti, Senior Vice President and Chief Financial Officer of Alexza. "We believe these advantages could benefit Alexza and our stockholders as we continue to transition from the development stage to commercialization."
"This is an exciting time for Alexza. As our October 11, 2010 PDUFA goal date approaches, we continue to scale-up our commercial manufacturing, and we are working with Biovail for the expected launch of our lead program AZ-004 (Staccato?reg; loxapine) in Q1 2011," said Thomas B. King, President and CEO of Alexza.
Alexza will determine, at its sole discretion, the timing, the dollar amount and the floor price per share of each draw under this facility, subject to certain conditions. When and if Alexza elects to use the facility, Alexza will issue shares to Azimuth at a small discount to the volume weighted average price of Alexza's common stock over a preceding period of trading days. Reedland Capital Partners, an Institutional Division of Financial West Group, Member FINRA/SIPC, will act as placement agent and receive a fee for its services at the time of any draw under the facility. Any shares sold under this facility will be sold pursuant to a shelf registration statement declared effective by the Securities and Exchange Commission on May 20, 2010.
Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
4:10 pm ET 05/26/2010- PR Newswire
MOUNTAIN VIEW, Calif., May 26 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has obtained a committed equity financing facility under which it may sell up to $25 million of its registered common stock to Azimuth Opportunity, Ltd. over a 24-month period. Alexza is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions. This facility replaces a similar facility that was established in March 2008 and expired after its 24-month term.
"This flexible financing facility is an important component of our portfolio of financing options, giving us the potential ability to raise capital quickly, at a competitive cost, and it may allow us to manage dilution more effectively by issuing shares in multiple tranches at times of our choosing over the next 24 months," said August J. Moretti, Senior Vice President and Chief Financial Officer of Alexza. "We believe these advantages could benefit Alexza and our stockholders as we continue to transition from the development stage to commercialization."
"This is an exciting time for Alexza. As our October 11, 2010 PDUFA goal date approaches, we continue to scale-up our commercial manufacturing, and we are working with Biovail for the expected launch of our lead program AZ-004 (Staccato?reg; loxapine) in Q1 2011," said Thomas B. King, President and CEO of Alexza.
Alexza will determine, at its sole discretion, the timing, the dollar amount and the floor price per share of each draw under this facility, subject to certain conditions. When and if Alexza elects to use the facility, Alexza will issue shares to Azimuth at a small discount to the volume weighted average price of Alexza's common stock over a preceding period of trading days. Reedland Capital Partners, an Institutional Division of Financial West Group, Member FINRA/SIPC, will act as placement agent and receive a fee for its services at the time of any draw under the facility. Any shares sold under this facility will be sold pursuant to a shelf registration statement declared effective by the Securities and Exchange Commission on May 20, 2010.
This is too easy...FIRE - SourceFire hod again
I have laughed out loud each time that ticker goes ripping by
Markets slugging it's way back CREE, SNDK, tech sector stocks ramping strongly
SLXP stong off today's opening market slough
Subscribe to Seasonality
Posted by: Chartinator Date: Wednesday, February 17, 2010 7:54:44 AM
In reply to: None Post # of 57744
Join us in chat! Real-time alerts, chart setups taught, nightly newsletters with momentum lists, and afternoon alerts!
http://stocktraderschat.com/tradingforum/seasonality_subscribe9.php#gpm1_2